Outpatient antibiotic prescribing and nonsusceptible streptococcus pneumoniae in the United States, 1996-2003

Clinical Infectious Diseases

Volumn 53, Issue 7, 2011, Pages 631-639

  Hicks, Lauri A ^a   Chien, Yu Wen ^b   Taylor, Thomas H ^a   Haber, Michael ^b   Klugman, Keith P ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE;

ARTICLE; DISEASE SURVEILLANCE; HUMAN; INVASIVE PNEUMOCOCCAL DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; MENINGITIS, PNEUMOCOCCAL; OUTPATIENTS; PNEUMOCOCCAL INFECTIONS; SELECTION, GENETIC; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 80052514833     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir443     Document Type: Article

References (39)

1. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and metaanalysis. Clin Infect Dis 2006; 42:788-97. (Pubitemid 43363934)
2. Paladino JA, Adelman MH, Schentag JJ, Iannini PB. Direct costs in patients hospitalised with community-acquired pneumonia after nonresponse to outpatient treatment with macrolide antibacterials in the US. Pharmaeconomics 2007; 25:677-83. (Pubitemid 47124169)
3. Daneman N, McGeer A, Green K, Low DE. Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432-8. (Pubitemid 44157150)
4. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992; 166:1346-53.
5. Costelloe C,Metcalfe C, Lovering A,Mant D,Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340:c2096.
6. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482-90. (Pubitemid 46209315)
7. Lipsitch M. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 2001; 32:1044-54. (Pubitemid 32299640)
8. Bronzwaer S, Cars O, Buchholz , et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8:278-82. (Pubitemid 34266265)
9. van de Sande-Bruinsma N, Grundmann H, Verloo D, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 2008; 14:1722-30.
10. Riedel S, Beckmann SE, Heilmann KP, et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26:485-90. (Pubitemid 47025039)
11. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46. (Pubitemid 36514704)
12. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
13. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196:1346-54. (Pubitemid 351412007)
14. Van Effelterre T, Moore MR, Fierens F, et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine 2010; 28:3650-60.
15. Croucher NJ, Harris SR, Fraser C, et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011; 331:430-4.
16. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24. (Pubitemid 32064785)
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
18. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9:424-30. (Pubitemid 36460076)
19. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
20. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009; 199:776-85.
21. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009; 302:758-66.
22. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000 [published correction appears in Emerg Infect Dis 2003; 9:609]. Emerg Infect Dis 2003; 9:432-7.
23. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987; 31:1948-54. (Pubitemid 18009567)
24. BergmanM, HuikkoS,HuovinenP, Paakkari P, Seppälä H. Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50:3646-50. (Pubitemid 44684876)
25. Skalet AH, Cevallos V, Ayele B, et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PloS Med 2010; 7:e1000377.
26. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857-62. (Pubitemid 33010237)
27. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15:1260-4.
28. Goossens H, Ferech M, Vander Stichele R, Elseviers M. ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87. (Pubitemid 40247914)
29. Dagan R, Barkai G, Givon-Lavi N, et al. Seasonality of antibioticresistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy? J Infect Dis 2008; 197:1094-102. (Pubitemid 351590044)
30. Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis 2005; 11:829-37. (Pubitemid 40720842)
31. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-97. (Pubitemid 40570238)
32. Pantosti A, Moro ML. Antibiotic use: the crystal ball for predicting antibiotic resistance. Clin Infect Dis 2005; 40:1298-300. (Pubitemid 40570239)
33. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40:159-64. (Pubitemid 34027619)
34. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176:1253-9. (Pubitemid 27460991)
35. Belongia EA, Sullivan BJ, Chyou P, Madagame E, Reed KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics 2001; 108:575-83. (Pubitemid 32786583)
36. Goossens H, Ferech M, Coenen S, Stephens P. European Surveillance of Antimicrobial Consumption Project Group. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007; 44:1091-5. (Pubitemid 46580279)
37. Steinman MA, Yang KY, Byron SC, Maselli JH, Gonzalez R. Variation in outpatient antibiotic prescribing in the United States. Am J Manag Care 2009; 15:861-8.
38. Hampton LM, Farley MM, Schaffner W, et al. Impact of changing definitions of penicillin resistance on vaccine effects against Streptococcus pneumoniae, United States, 1998-2008 [abstract]. In: Program and Abstracts of the International Conference on Emerging Infectious Diseases (Atlanta). Washington, DC: American Society of Microbiology, 2010; 82-pp.
39. Huttner B, Goossens H, Verheij T, Harbarth S. on behalf of the CHAMP consortium. Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in highincome countries. Lancet Infect Dis 2010; 10:17-31.